SCHEDULE 13G/A: Armistice Capital and Steven Boyd Maintain 9.99% Stake in Dermata Therapeutics

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a continued 9.99% beneficial ownership stake in Dermata Therapeutics, Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Dermata Therapeutics, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 276,422 shares of Dermata Therapeutics, Inc. Common Stock.
• This ownership represents 9.99% of the total outstanding shares of Dermata Therapeutics, Inc. Common Stock.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities held by the Master Fund.
• Both Armistice Capital, LLC and Steven Boyd have shared voting and shared dispositive power over all 276,422 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing disclosing beneficial ownership. The maintenance of a significant stake by an institutional investor like Armistice Capital can be viewed as a neutral to slightly positive signal, indicating continued investment interest without any stated activist intent.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, maintain a substantial 9.99% beneficial ownership stake in Dermata Therapeutics, Inc.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent to change control.

Negatives

• The document does not contain information regarding the operational or financial performance of Dermata Therapeutics, Inc., thus no specific negatives related to the company's business are present.

Risks

• The joint filing statement notes that each reporting person is responsible for the timely filing, completeness, and accuracy of their own information, but not for others, except where they know or have reason to believe information is inaccurate.

Future Outlook

The document is a regulatory filing disclosing beneficial ownership and does not contain any forward-looking statements or guidance from Dermata Therapeutics, Inc. or the reporting persons regarding the issuer's future outlook.

Management Comments

• The Reporting Persons certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This Schedule 13G filing is a standard regulatory disclosure of significant beneficial ownership and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector where Dermata Therapeutics, Inc. operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which may influence investor sentiment and perception of stability.

Key Dates

Keywords

Dermata Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management